--- title: "Advanced Biomed (ADVB) news: going concern" url: "https://aibio.space/companies/advanced-biomed/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ADVB going concern news: Advanced Biomed files NT 10-Q, says review of September 30, 2025 quarter is not finished. Advanced Biomed Inc." --- ADVB Advanced Biomed Inc. NASDAQ · Taiwan # Advanced Biomed (ADVB) news ADVB going concern news Distress · 2026-09-28 ## [Advanced Biomed files late notice for annual report as audit is not complete](https://aibio.space/news/advanced-biomed-files-late-notice-annual-report-audit-not-complete/) Advanced Biomed told the SEC it could not file its annual report for the year ended June 30, 2026 on time because the audit was not finished. The notice does not name the auditor or explain the delay beyond that. ## Latest Advanced Biomed news 1. 2025-11-14 Distress [Advanced Biomed files NT 10-Q, says review of September 30, 2025 quarter is not finished](https://aibio.space/news/advanced-biomed-files-nt-10-q-says-review-september-30-2025-quarter/) Advanced Biomed, which carried a going-concern warning and a Nasdaq bid price notice in its last annual report, says the review of its September 30, 2025 quarter is not finished. 2. 2025-07-24 Listings [Advanced Biomed gets Nasdaq bid price notice, has until January 14, 2026 to comply](https://aibio.space/news/advanced-biomed-gets-nasdaq-bid-price-notice-has-until-january-14-2026/) The stock closed below $1.00 for 32 consecutive business days. Shares keep trading on the Nasdaq Capital Market under ADVB during the compliance period. ## Advanced Biomed at a glance - **Ticker**: ADVB - **Listing**: NASDAQ - **Country**: Taiwan - **Cash, Jun 30, 2026**: $385,535 ### Related companies - [Bioray Biotech Co.](https://aibio.space/companies/bioray-biotech/) TPEX: 7561 - [Libo Pharma](https://aibio.space/companies/libo-pharma/) TPEX: 7888 - [Bionet](https://aibio.space/companies/bionet/) TPEX: 1784 - [Syngen Biotech Co.](https://aibio.space/companies/syngen-biotech/) TPEX: 8279 - [HanchorBio](https://aibio.space/companies/hanchorbio/) TWSE: 7827 - [Greenyn Biotechnology Co.](https://aibio.space/companies/greenyn-biotechnology/) TPEX: 6846 - [Lin BioScience](https://aibio.space/companies/lin-bioscience/) TPEX: 6696 - [Caliway Biopharmaceuticals Co](https://aibio.space/companies/caliway-biopharmaceuticals/) TWSE: 6919 ### Also on NASDAQ - [Biogen](https://aibio.space/companies/biogen/) BIIB - [BIOMERICA INC](https://aibio.space/companies/biomerica/) BMRA - [BeyondSpring](https://aibio.space/companies/beyondspring/) BYSI - [Edesa Biotech](https://aibio.space/companies/edesa-biotech/) EDSA - [Relmada Therapeutics](https://aibio.space/companies/relmada-therapeutics/) RLMD - [Vera Therapeutics](https://aibio.space/companies/vera-therapeutics/) VERA ## What Advanced Biomed does Advanced Biomed Inc. is a Nevada holding company that has moved from biomedical devices into enterprise artificial intelligence. In April 2026 it acquired 100% of the equity of Acellent Technologies (Hong Kong) Co. Limited, which develops and operates the FinTruth Financial Verification Agent Platform. FinTruth is an enterprise AI platform designed to compare and verify financial analysis and AI-generated financial content against underlying source documents and financial rules. Target customers include commercial banks, securities firms, insurance companies, asset managers, auditing and professional-services firms, and financial technology companies. The company sold its biomedical operations in December 2025 and June 2026. Those operations had developed lab devices and chemicals to find and study cancer cells in a patient's blood, and the company says it has terminated that business. During the fiscal year ended June 30, 2026, it generated approximately $127,637 (HK$1,000,000) in revenue from FinTruth operations. The company expects to earn enterprise subscription and usage-based API fees. It reports that the ELOC Agreement with Helena Global Investment Opportunities I Ltd., for up to $25,000,000 of common stock, terminated effective July 21, 2026. | Product or program | What it is | Stage | |---|---|---| | FinTruth Financial Verification Agent Platform | Enterprise AI platform that verifies financial analysis against source documents | Commercial engagement with prospective customers | | A+Pre and AC-1000 devices | Lab devices that prepare blood samples and separate cancer cells from blood | Biomedical business terminated | Summarised from the company's [10-K filed Oct 13, 2026](https://www.sec.gov/Archives/edgar/data/1941029/000121390026109029/ea0307457-10k_advanced.htm). ## Advanced Biomed annual financials | Line | FY ended Jun 30, 2026 | FY ended Jun 30, 2025 | |---|---|---| | Revenue | [$127,637](https://www.sec.gov/Archives/edgar/data/1941029/000121390026109029/) | | | Research and development | | [$909,771](https://www.sec.gov/Archives/edgar/data/1941029/000121390025097465/) | | Net income (loss) | [$6.7 million](https://www.sec.gov/Archives/edgar/data/1941029/000121390026109029/) | [-$3.3 million](https://www.sec.gov/Archives/edgar/data/1941029/000121390026109029/) | | Cash from operations | [-$1.9 million](https://www.sec.gov/Archives/edgar/data/1941029/000121390026109029/) | [-$5.8 million](https://www.sec.gov/Archives/edgar/data/1941029/000121390026109029/) | | Cash and equivalents | [$385,535](https://www.sec.gov/Archives/edgar/data/1941029/000121390026109029/) | [$31,139](https://www.sec.gov/Archives/edgar/data/1941029/000121390026109029/) | Latest balance sheet, Jun 30, 2026 (10-K): cash and equivalents $385,535. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Advanced Biomed Has Advanced Biomed issued a going-concern warning? Our latest story on this, dated Nov 14, 2025: "Advanced Biomed files NT 10-Q, says review of September 30, 2025 quarter is not finished". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/advanced-biomed-files-nt-10-q-says-review-september-30-2025-quarter/). What is the ticker symbol of Advanced Biomed? Advanced Biomed Inc. trades under the ticker ADVB on NASDAQ. Where is Advanced Biomed listed? Advanced Biomed Inc. is listed on NASDAQ. What is the SEC CIK of Advanced Biomed? The SEC Central Index Key (CIK) for Advanced Biomed Inc. is 1941029. Its filings are on SEC EDGAR. How many shares does Advanced Biomed have outstanding? 1,652,133 shares as of 2026-10-13, per the cover page of its 10-K filed 2026-10-13. Which country or territory is Advanced Biomed listed under? Our directory records Advanced Biomed Inc. under Taiwan. What does Advanced Biomed do? Our directory classifies Advanced Biomed Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Advanced Biomed? The ISIN recorded for Advanced Biomed Inc. is US00752P2039. Does aibio.space cover Advanced Biomed? aibio.space lists Advanced Biomed Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Advanced Biomed incorporated? SEC records list its state or country of incorporation as NV. What does Advanced Biomed develop? Advanced Biomed Inc. is a Nevada holding company that has moved from biomedical devices into enterprise artificial intelligence. In April 2026 it acquired 100% of the equity of Acellent Technologies (Hong Kong) Co. Limited, which develops and operates the FinTruth Financial Verification Agent Platform. What is FinTruth Financial Verification Agent Platform from Advanced Biomed? FinTruth Financial Verification Agent Platform: Enterprise AI platform that verifies financial analysis against source documents Stage: Commercial engagement with prospective customers. What is A+Pre and AC-1000 devices from Advanced Biomed? A+Pre and AC-1000 devices: Lab devices that prepare blood samples and separate cancer cells from blood Stage: Biomedical business terminated. What was Advanced Biomed's revenue last year? $127,637 for the fiscal year ended Jun 30, 2026, as reported to the SEC. Is Advanced Biomed profitable? Advanced Biomed Inc. reported net income of $6.7 million for the fiscal year ended Jun 30, 2026, and used $1.9 million of cash in operations, per its annual report to the SEC. ## Investor discussion: Advanced Biomed Members talk about Advanced Biomed (ADVB). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Advanced Biomed, newest first. Each line links the filing it comes from. 1. 2026-09-28 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1941029/000121390026104071/ea030671201-nt10k_advanced.htm) 2. 2026-07-17 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1941029/000121390026079233/ea0298321-8k_advanced.htm) 3. 2026-05-01 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,3.02,5.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1941029/000121390026051028/ea0288766-8k_advanced.htm) 4. 2026-03-16 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1941029/000121390026028330/ea0281688-8k_advanced.htm) 5. 2026-02-26 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1941029/000121390026020807/ea027844801ex99-1.htm) 6. 2026-02-02 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1941029/000121390026010809/ea0274958-8k_advanced.htm) 7. 2026-01-21 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1941029/000121390026006281/ea027358501-8k_advanced.htm) 8. 2025-12-30 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1941029/000121390025126584/ea027115701ex99-1_advanced.htm) 9. 2025-11-14 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1941029/000121390025110809/ea0265672-nt10q_advanced.htm) 10. 2025-09-30 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1941029/000121390025093917/ea0259117-nt10k_advanced.htm) 11. 2025-07-24 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1941029/000121390025067328/ea025015701-8k_advanced.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ADVB on TradingView](https://www.tradingview.com/symbols/NASDAQ-ADVB/). ## SEC filings and registration - **SEC name**: Advanced Biomed Inc. - **CIK**: 1941029 - **Industry (SIC)**: Services-Medical Laboratories (8071) - **US tickers**: ADVB (Nasdaq) - **State or country of incorporation**: NV - **Fiscal year ends**: June 30 - **Filer category**: Non-accelerated filer
Smaller reporting company
Emerging growth company - **Business address**: 401 RYLAND ST, RENO, NV, 89502 - **Phone**: 86-21-20510823 - **Shares outstanding**: 1,652,133 as of 2026-10-13 (10-K filed 2026-10-13) ### Recent filings (8-K and 6-K are the company's own announcements) - [10-K](https://www.sec.gov/Archives/edgar/data/1941029/000121390026109029/ea0307457-10k_advanced.htm) filed 2026-10-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1941029/000121390026079233/ea0298321-8k_advanced.htm) filed 2026-07-17 - [8-K](https://www.sec.gov/Archives/edgar/data/1941029/000121390026074306/ea0296511-8k_advanced.htm) filed 2026-07-01 - [8-K](https://www.sec.gov/Archives/edgar/data/1941029/000121390026073735/ea0296529-8k_advanced.htm) filed 2026-06-30 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1941029/000121390026065017/ea0293159-def14a_advanced.htm) filed 2026-06-04 - [10-Q](https://www.sec.gov/Archives/edgar/data/1941029/000121390026057226/ea0289967-10q_advanced.htm) filed 2026-05-15 - [8-K](https://www.sec.gov/Archives/edgar/data/1941029/000121390026051028/ea0288766-8k_advanced.htm) filed 2026-05-01 - [8-K](https://www.sec.gov/Archives/edgar/data/1941029/000121390026043557/ea0286291-8k_advanced.htm) filed 2026-04-14 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001941029), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Advanced Biomed Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ADVB, recorded under Taiwan. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Advanced Biomed Inc. - **Ticker**: ADVB - **Listing**: NASDAQ - **Country or territory**: Taiwan - **Business scope**: Biotechnology - **ISIN**: US00752P2039 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-ADVB/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/advanced-biomed/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Advanced Biomed (ADVB) news: going concern", 2026-10-31, https://aibio.space/companies/advanced-biomed/